EXELA HOLDINGS
GenericsEXELA HOLDINGS is a generic drug manufacturer focused on Immunology, Gastroenterology.
EXELA HOLDINGS's Key Drugs
EXELA HOLDINGS's core commercial portfolio centers on DICLOFENAC SODIUM AND MISOPROSTOL, spanning Immunology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
EXELA HOLDINGS's Recent FDA Approvals
New NDA/BLA approvals for EXELA HOLDINGS over the last two years — novel drugs only, excluding generics and label supplements.
EXELA HOLDINGS's Therapeutic Areas
EXELA HOLDINGS's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EXELA HOLDINGS's Top Competitors
EXELA HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EXELA HOLDINGS Pipeline Snapshot
Active clinical trials for EXELA HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DICLOFENAC SODIUM AND MISOPROSTOL leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-03-14
- Latest
- 2017-12-27
- Applications
- 1